Edwards N C, Yuan M, Nolan O, Pawade T A, Oelofse T, Singh H, Mehrzad H, Zia Z, Geh J I, Palmer D H, May C J H, Ayuk J, Shah T, Rooney S J, Steeds R P
Departments of Cardiology (N.C.E., M.Y., O.N., T.A.P., R.P.S.), Anaesthesia (T.O., H.S.), Radiology (H.M., Z.Z.), Oncology (J.I.G.), Endocrinology (C.J.H.M., J.A.), Hepatology (T.S.), and Cardiothoracic Surgery (S.J.R.), Queen Elizabeth Hospital Birmingham, Birmingham B15 2TT, United Kingdom; and Department of Molecular and Clinical Cancer Medicine (D.H.P.), University of Liverpool, Liverpool L69 3BX, United Kingdom.
J Clin Endocrinol Metab. 2016 Jan;101(1):183-90. doi: 10.1210/jc.2015-3295. Epub 2015 Nov 18.
Carcinoid heart disease (NET-CHD) is associated with the development of symptom-limited exercise capacity and high rates of morbidity and mortality.
This study sought to determine the survival, cardiac function, and functional class following surgery.
DESIGN AND SETTING, AND PATIENTS: This was a retrospective observational cohort study between 2005 and 2015 at a European Centre of Excellence for Neuroendocrine Tumours, Queen Elizabeth Hospital Birmingham. England consisting of 62 consecutive patients referred to the NET-Cardiology Service.
Subjects were assessed at referral using transthoracic echocardiography (with saline contrast) and transesophageal echocardiography, and 77% with confirmed NET-CHD underwent cardiovascular magnetic resonance imaging. Symptomatic patients with concomitant severe valvular dysfunction were referred for surgery with stable NET disease.
Survival of patients with proven NET-CHD following medical and surgical treatments was measure.
In total, 47/62 patients were diagnosed with NET-CHD. Thirty-two patients (68%) underwent surgery with bioprosthetic valve replacements in all subjects; tricuspid, n = 31; pulmonary, n = 30; mitral, n = 3; and aortic, n = 3. Four patients underwent concomitant coronary artery bypass grafting. There were 4 (13%) early post-operative deaths. One- and 2-y survival rates after surgery were 75 and 69% compared with 45 and 15% in un-operated patients. Post-operatively, functional class was improved (pre-New York Heart Association Classification [NYHA], 2.6 [0.5] vs post-NYHA, 1.7 [1.1]), P < .05, right-ventricular (RV) size was reduced (136 ml/m(2) [25] vs 71 ml/m(2) [7]; P < .01) with preserved RV ejection fraction (61% ± 9 vs 55% ± 10; P = .26).
Valve surgery improved functional class and resulted in RV reverse remodelling with improved survival rates at 2 y compared with those not proceeding to operation. These data highlight the importance of close collaboration between NET clinicians, cardiology, and cardiothoracic surgery teams. Early referral can improve functional capacity but more research is needed to define the selection of appropriate candidates and randomized data are needed to define the effect of surgery on prognosis.
类癌性心脏病(NET-CHD)与症状受限的运动能力以及高发病率和死亡率相关。
本研究旨在确定手术后的生存率、心脏功能和功能分级。
设计、地点及患者:这是一项2005年至2015年在英国伯明翰伊丽莎白女王医院欧洲神经内分泌肿瘤卓越中心进行的回顾性观察队列研究。该研究纳入了连续转诊至NET心脏病服务部门的62例患者。
在转诊时使用经胸超声心动图(含生理盐水造影剂)和经食管超声心动图对受试者进行评估,77%确诊为NET-CHD的患者接受了心血管磁共振成像检查。有症状且伴有严重瓣膜功能障碍的患者在NET疾病稳定时被转诊接受手术。
测量经证实患有NET-CHD的患者在药物和手术治疗后的生存率。
总共62例患者中有47例被诊断为NET-CHD。32例患者(68%)接受了手术,所有患者均进行了生物瓣膜置换;三尖瓣置换31例;肺动脉瓣置换30例;二尖瓣置换3例;主动脉瓣置换3例。4例患者同时接受了冠状动脉搭桥术。术后早期死亡4例(13%)。手术后1年和2年的生存率分别为75%和69%,而未手术患者分别为45%和15%。术后,功能分级得到改善(术前纽约心脏协会分级[NYHA]为2.6[0.5],术后为1.7[1.1]),P<0.05,右心室(RV)大小减小(136 ml/m²[25]对71 ml/m²[7];P<0.01),右心室射血分数保持不变(61%±9对55%±10;P = 0.26)。
瓣膜手术改善了功能分级,导致右心室逆向重构,与未进行手术的患者相比,2年生存率有所提高。这些数据突出了NET临床医生、心脏病学和心胸外科团队密切合作的重要性。早期转诊可改善功能能力,但需要更多研究来确定合适的候选者选择,并且需要随机数据来确定手术对预后的影响。